Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment

Data from two open-label trials (PRIOR and CURRENT) of women with postmenopausal osteoporosis or osteopenia were evaluated to assess whether monthly oral and quarterly intravenous (IV) ibandronate dosing improved self-reported gastrointestinal (GI) tolerability for patients who had previously experi...

Descripción completa

Detalles Bibliográficos
Autores principales: Derman, Richard, Kohles, Joseph D, Babbitt, Ann
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762360/
https://www.ncbi.nlm.nih.gov/pubmed/19851511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762360/
https://www.ncbi.nlm.nih.gov/pubmed/19851511

Ejemplares similares